Induction of systemic, mucosal, and cellular immunity against SARS-CoV-2 in mice vaccinated by trans-airway with a S1 protein combined with a pulmonary surfactant-derived adjuvant SF-10.

Takashi KimotoSatoko SakaiKeiko KamedaRyoko MoritaEtsuhisa TakahashiYasuo ShinoharaHiroshi Kido

Published in: Influenza and other respiratory viruses (2023)

Based on the need for effective systemic, respiratory, and cellular immunity, the S1-SF-10-TA vaccine seems promising mucosal vaccine against respiratory infection of SARS-CoV-2.

Keyphrases

sars cov
respiratory syndrome coronavirus
ulcerative colitis
early stage
pulmonary hypertension
respiratory tract
high fat diet induced
amino acid
protein protein
binding protein
type diabetes
metabolic syndrome
adipose tissue
insulin resistance
coronavirus disease
wild type